Protara Therapeutics Stock Performance
| TARA Stock | USD 3.35 0.04 1.18% |
The company holds a Beta of 1.38, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Protara Therapeutics will likely underperform. At this point, Protara Therapeutics has a negative expected return of -0.29%. Please make sure to check Protara Therapeutics' accumulation distribution, and the relationship between the potential upside and day median price , to decide if Protara Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Protara Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.8 | Five Day Return 6.6 | Year To Date Return (39.25) | Ten Year Return (99.53) | All Time Return (99.16) |
Last Split Factor 1:40 | Dividend Date 2020-01-10 | Last Split Date 2020-01-10 |
1 | Acquisition by Zummo Jacqueline of 146000 shares of Protara Therapeutics at 4.53 subject to Rule 16b-3 | 05/16/2025 |
2 | Protara Therapeutics Appoints New Chief Commercial Officer TARA Stock News | 06/02/2025 |
3 | Acquisition by Conkling William of 200000 shares of Protara Therapeutics at 3.3 subject to Rule 16b-3 | 06/04/2025 |
4 | TARA Media Fortifies Ad Supply Path Refinement Process with Pixalate Partnership | 06/10/2025 |
5 | Protara Therapeutics Marching On To A Hopefully Eventful Back Half Of 2025 - Seeking Alpha | 06/13/2025 |
6 | Disposition of 300000 shares by Jesse Shefferman of Protara Therapeutics subject to Rule 16b-3 | 06/24/2025 |
7 | Disposition of 3400 shares by Jesse Shefferman of Protara Therapeutics subject to Rule 16b-3 | 06/26/2025 |
8 | Disposition of 3367 shares by Jesse Shefferman of Protara Therapeutics subject to Rule 16b-3 | 06/27/2025 |
9 | Protara Therapeutics added to the Russell 3000 index | 06/30/2025 |
10 | Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 07/01/2025 |
11 | What drives Protara Therapeutics Inc. stock price - Unprecedented profits - Jammu Links News | 07/18/2025 |
12 | What drives Protara Therapeutics Inc. stock price - Unmatched market performance - jammulinksnews.com | 07/23/2025 |
| Begin Period Cash Flow | 40.3 M | |
| Total Cashflows From Investing Activities | 19.2 M |
Protara Therapeutics Relative Risk vs. Return Landscape
If you would invest 432.00 in Protara Therapeutics on April 25, 2025 and sell it today you would lose (94.00) from holding Protara Therapeutics or give up 21.76% of portfolio value over 90 days. Protara Therapeutics is currently does not generate positive expected returns and assumes 4.564% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Protara, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Protara Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protara Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Protara Therapeutics, and traders can use it to determine the average amount a Protara Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0636
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TARA |
Estimated Market Risk
| 4.56 actual daily | 40 60% of assets are more volatile |
Expected Return
| -0.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Protara Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Protara Therapeutics by adding Protara Therapeutics to a well-diversified portfolio.
Protara Therapeutics Fundamentals Growth
Protara Stock prices reflect investors' perceptions of the future prospects and financial health of Protara Therapeutics, and Protara Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protara Stock performance.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 10.66 M | ||||
| Shares Outstanding | 38.58 M | ||||
| Price To Book | 0.83 X | ||||
| EBITDA | (49.15 M) | ||||
| Net Income | (44.6 M) | ||||
| Cash And Equivalents | 98.46 M | ||||
| Cash Per Share | 8.74 X | ||||
| Total Debt | 4.48 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 28.94 X | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (35.81 M) | ||||
| Earnings Per Share | (1.49) X | ||||
| Market Capitalization | 130.79 M | ||||
| Total Asset | 181.45 M | ||||
| Retained Earnings | (244.98 M) | ||||
| Working Capital | 161.19 M | ||||
About Protara Therapeutics Performance
By analyzing Protara Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Protara Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Protara Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protara Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.5 K | 839 | |
| Return On Tangible Assets | (0.25) | (0.26) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.25) | (0.26) | |
| Return On Equity | (0.27) | (0.28) |
Things to note about Protara Therapeutics performance evaluation
Checking the ongoing alerts about Protara Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protara Therapeutics generated a negative expected return over the last 90 days | |
| Protara Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (44.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protara Therapeutics currently holds about 98.46 M in cash with (35.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Protara Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: What drives Protara Therapeutics Inc. stock price - Unmatched market performance - jammulinksnews.com |
- Analyzing Protara Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protara Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protara Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protara Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protara Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protara Therapeutics' stock. These opinions can provide insight into Protara Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Protara Stock analysis
When running Protara Therapeutics' price analysis, check to measure Protara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protara Therapeutics is operating at the current time. Most of Protara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protara Therapeutics' price. Additionally, you may evaluate how the addition of Protara Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |